Arvinas Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
The option exercise price equals the grant-date closing share price, with a 10-year term.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Arvinas (Nasdaq: ARVN) granted equity inducement awards to one newly hired employee, effective September 28, 2026.
The awards comprise an option to purchase 64,766 common shares and 42,388 restricted stock units. The option has a 10-year term and an exercise price of $7.51 per share, equal to the stock’s closing price on the grant date. Both awards vest over four years, subject to continued service as an employee or other service provider through the applicable vesting dates. They were granted under Nasdaq Listing Rule 5635(c)(4), outside Arvinas’ stock incentive plan.
Positive
- None.
Negative
- Minor point. Forward-looking: it has not happened yet and may not happen.64,766 options at $7.51 per share and 42,388 restricted stock units create potential dilution, subject to vesting.
News Explained
The September 28 option grant is not itself a share issuance; if exercised and newly issued shares are delivered, the share count would rise and existing holders’ percentage ownership would fall.
Key Figures
- Option shares
- 64,766 shares
- Option award to one newly hired employee
- Restricted stock units
- 42,388 RSUs
- RSU award to one newly hired employee
- Exercise price
- $7.51 per share
- Option exercise price; equal to the closing price on the grant date
- Option term
- 10 years
- Term of the option award
- Vesting period
- Four years
- Option and RSU awards, subject to continued service
Key Terms
restricted stock units financial
nasdaq listing rule 5635(c)(4) regulatory
AI-generated analysis. How Rhea-AI works. Not financial advice.
NEW HAVEN, Conn., Sept. 29, 2026 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN) (“Arvinas” or the “Company”), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced the Company granted an option to purchase 64,766 shares of common stock (the “Option Award”) and 42,388 restricted stock units (“RSU”) to one newly hired employee (the “RSU Award”). The Option Award and RSU Award were each granted as of September 28, 2026 (the “Grant Date”) in accordance with Nasdaq Listing Rule 5635(c)(4) and not pursuant to Arvinas’ stock incentive plan.
The option has a 10-year term and an exercise price of
About Arvinas
Arvinas (Nasdaq: ARVN) is a clinical-stage biotechnology company dedicated to improving the lives of patients suffering from debilitating and life-threatening diseases. Through its PROTAC (PROteolysis TArgeting Chimera) protein degrader platform, Arvinas is pioneering the development of protein degradation therapies designed to harness the body’s natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. Arvinas, with its partner Pfizer, developed the first U.S. Food and Drug Administration (FDA)-approved PROTAC, a type of heterobifunctional protein degrader, which has been outlicensed to Rigel Pharmaceuticals, Inc. for exclusive global development, manufacturing, and commercialization.
Arvinas is currently progressing multiple investigational drugs through clinical development programs, including ARV-393, targeting BCL6 for relapsed/refractory non-Hodgkin Lymphoma; ARV-102, targeting LRRK2 for neurodegenerative disorders; ARV-027, targeting the polyglutamine-expanded androgen receptor, or polyQ-AR, in skeletal muscle for spinal-bulbar muscular atrophy, also known as Kennedy’s disease; and ARV-6723, targeting HPK1 for advanced solid tumors. Arvinas has also advanced ARV-806, targeting KRAS G12D for solid tumors, in the clinic, and previously announced plans to seek an out-licensing agreement for any additional clinical trials of ARV-806, including dose expansion or combination clinical trials. Arvinas is headquartered in New Haven, Connecticut. For more information about Arvinas, visit www.arvinas.com and connect on LinkedIn and X.
Contacts
Investors:
Jeff Boyle
+1 (347) 247-5089
Jeff.Boyle@arvinas.com
Media:
Kirsten Owens
+1 (203) 584-0307
Kirsten.Owens@arvinas.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What equity inducement awards did Arvinas grant to its new employee?
Arvinas granted an option to purchase 64,766 common shares and 42,388 restricted stock units to one newly hired employee. Both awards were granted as of September 28, 2026, under Nasdaq Listing Rule 5635(c)(4), outside the company’s stock incentive plan.
How do Arvinas’ new employee inducement awards vest?
The option vests over four years, with 25% vesting on the first anniversary of the employee’s start date and 1/48th of the original shares vesting monthly thereafter. The restricted stock units vest in four equal annual installments through the fourth start-date anniversary. Both schedules require continued service as an employee or other service provider through each vesting date.